Enrichment Program
Validation Of Predicted Sars-cov-2 Nucleocapsid Protein Peptides (np104-122, Np125-144, And Np166-183) Immunogenicity In Pbmc Samples From The Indonesian Population
This study investigates the potential of T-cell-mediated immunity in combating SARS-CoV-2, given the concerns about the high mutation rate in the virus's S protein and its potential impact on vaccine efficacy. The prevalent HLA class II alleles in the Indonesian population, namely HLA-DRB1*12:02, HLA-DRB1*15:02, and HLA-DRB1*07:01, play a crucial role in presenting viral peptide antigens to the population. Despite their significance, limited research exists on SARS-CoV-2 peptides binding to these specific HLA alleles. Previous immunoinformatics studies had predicted peptides from the N protein of SARS-CoV-2 that could bind to these HLAs. This study validated the immunogenicity of these peptides using an IFN-γ ELISpot assay on 23 PBMC samples. Positive T-cell responses were observed for the predicted peptides, with eight responses for NP 104-122 , five for NP 125-144 , and one for NP 166-183 . Furthermore, ELISA was performed on 24 serum samples, revealing significant differences in anti-SARS-CoV-2 (N) IgG antibody levels between donors with a history of COVID-19 infection (47.17±22.54 μg/ml) and those without (26.76±12.91 μg/ml) (p-value=0.036). Notably, negative correlations were identified between T-cell and antibody responses and the time elapsed since a positive COVID-19 test, emphasizing the dynamic nature of immune responses over time. It was noteworthy that the decline of antibody responses was greater compared to T-cell response, highlighting the importance of understanding the role of T cells in long-term immunity
No other version available